Citigroup Starts Eli Lilly with a "Buy" Rating; Fiscal Cliff Sequestration Consequences Limited (LLY)

Citigroup Starts Eli Lilly with a “Buy” Rating; Fiscal Cliff Sequestration Consequences Limited (LLY)

RSS

Citigroup initiated coverage on pharmaceutical company Eli Lilly & Co. (LLY) on Friday.

The analysts start LLY off with a “Buy” rating and a price target of $55, a +13% upside to Thursday’s closing price of $48.58

The firm said that they believe the risks of sequestration due to the “fiscal cliff,” meaning a cut to Medicare part D drug spending, would be small for LLY.

Eli Lilly shares were up 17 cents, or +0.35%, in premarket trading on Friday.

The Bottom Line
Shares of Eli Lilly (LLY) have a 4.03% dividend yield, based on last night’s closing stock price of $48.58. The stock has technical support in the $44-$46 price area. If the shares can firm up, we see overhead resistance around the $51-$52 price levels.

Eli Lilly & Co. (LLY) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Free Updates

Join over 100,000 investors who get the latest news from Dividend.com.

Best Dividend Stocks

Looking for stocks that are poised for growth and pay solid dividends? Visit our list of the:

Best Dividend Stocks

Partner Center

Best CD Rates

Sitting on some extra cash and looking for the most current and profitable CD Rates?

Get The Best CD Rates

14 Day Free Trial

Earn more from your dividend portfolio within the next 14 days.

Sign Up Today